Pharmacel 112 is a spray-dried microcrystalline cellulose grade distributed under the product descriptor “Pharmacel 112 Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable.” The descriptor is a trade-level designation; in formulation practice the material functions as a compendial filler-binder-disintegrant rather than an active pharmacological ingredient. The substance is produced by controlled acid hydrolysis of purified α-cellulose pulp, followed by neutralization, washing, mechanical attrition, and spray drying. The manufacturing route generates low-moisture, porous, largely spherical particles with a nominal mean particle size of 100 µm as determined by laser diffraction under Ph. Eur. 2.9.31 / USP <429>. The product meets the current microcrystalline cellulose monographs of USP-NF, Ph. Eur., and JP.

The grade is differentiated from general-purpose microcrystalline cellulose by a supplier-tightened loss-on-drying limit of ≤ 3.0%, compared with the compendial limit of ≤ 5.0%. That reduction in moisture is the principal reason the grade is specified for moisture-sensitive active pharmaceutical ingredients. The degree of polymerization is controlled to not more than 350. The pH of an aqueous dispersion is 5.0–7.0 when measured by Ph. Eur. 2.2.3 / USP <791>. Residue on ignition is ≤ 0.1% by Ph. Eur. 2.4.16 / USP <281>. Conductivity is ≤ 75 µS/cm by Ph. Eur. 2.2.38 / USP <645>. The typical bulk density is 0.30–0.34 g/cm³ by Ph. Eur. 2.9.34 / USP <616>. These properties are relevant to both solid oral dosage forms and injectable suspensions because they define the material’s purity, ionic load, and water content before processing.

Regulatory filings should identify the material by its compendial monograph and manufacturer. The FDA Inactive Ingredient Database lists microcrystalline cellulose for oral and injectable routes, but route-specific maximum potency levels must be checked for the intended dosage form because the injection route has more restrictive limits. The product is not an active pharmaceutical ingredient; it is a pharmacopoeial excipient used to build the tablet, capsule, granule, or injectable suspension matrix.

How Does the Low-Moisture 100 µm Grade Perform in Direct Compression and Capsule Filling?

In direct compression, the material is blended with an active and lubricant and fed through a rotary tablet press. The combination of porous particle morphology and plastic deformation under pressure contributes to compact formation at applied forces commonly used on production machines. On a 16-station rotary press, compression forces between 5 kN and 25 kN typically produce tablets with acceptable hardness, but the exact force depends on active load and punch geometry. Published data for this specific configuration is limited. The material is not brittle in the manner of lactose monohydrate; it consolidates by plastic flow, which reduces capping tendency but increases ejection force if lubricant levels are too low. Magnesium stearate at 0.25–1.0 wt% is commonly used. Mixing with hydrophobic lubricants beyond 5 min may reduce tablet tensile strength because the lubricant coats the plastic-deforming surfaces.

Flow into the die is influenced by the particle size. A D50 of 100 µm offers lower surface area and better flow than a 50 µm grade, but less flow than an 180 µm grade. In direct compression, segregation of active particles should be monitored when the active particle size differs greatly from the microcrystalline cellulose. For low-dose products, geometric blending or pre-milling may be required. The material’s bulk density of 0.30–0.34 g/cm³ supports consistent die fill, but head height and feed-frame speed must be optimized to avoid overdosing in deep fill cams.

For capsule filling on dosator or tamping-pin machines, the low-moisture grade reduces wetting of the powder bed and may improve lubrication of the dosator. However, static charge can increase at very low relative humidity below 20%. Adjustment of filling machine humidity to 40–60% RH is a typical control. The powder should not be exposed to conditions above 60% RH; moisture gain will raise the loss on drying and reduce the low-moisture benefit. Loss on drying should be verified by Ph. Eur. 2.2.32 / USP <731> before and after holding steps.

Wet granulation with Pharmacel 112 requires a liquid addition endpoint established by torque or power draw rather than fixed water addition, because the same powder lot may show small shifts in water absorption. In a high-shear mixer, purified water or an aqueous binder solution is added until the wet mass reaches a plastic, cohesive state. A typical water range is 25–35 wt% of the dry mix for microcrystalline cellulose-based formulations, but published data for this specific configuration is limited. Overgranulation leads to hard granules that resist compression and can produce capping; undergranulation produces weak, friable granules that segregate on the press. The granule is then dried in a fluid-bed dryer at inlet air temperature 40–60 °C to a target loss on drying of 1.5–3.0%. Drying above 60 °C is not necessary for this grade and may overdry the granule, increasing electrostatic charging and reducing compactibility. After drying, the granules are passed through a 0.8–1.2 mm screen. The D50 of the milled granule is typically larger than the starting material, so final blend flow and compression behavior must be re-evaluated.

Dry granulation by roller compaction is also feasible. The material may be compacted into ribbons at roll pressures from 3–8 MPa and milled to granules. The low-moisture characteristic is an advantage when the active is sensitive to hydrolysis; no aqueous binder is introduced. Ribbon density and granule porosity must be controlled because overcompaction reduces the remaining binding capacity of the granules. Published data for this specific configuration is limited.

Injectable suspension processing imposes additional requirements. The material is not suitable for intravenous administration unless a specific finished-product safety case has been validated; particulate cellulose can pose an embolic hazard by the intravenous route. For intramuscular or subcutaneous suspension formulations, it may serve as a suspending agent and viscosity modifier. Batch release should include bacterial endotoxin testing by Ph. Eur. 2.6.14 / USP <85>. The finished product must meet its specific bacterial endotoxin limit and sterility standard. Terminal sterilization by moist heat at 121 °C for 15 min may be applied, but the effect on suspension viscosity, particle aggregation, and resuspendability must be evaluated. The particle size distribution of the injectable suspension should be controlled by the finished-product specification; the excipient D50 of 100 µm may require milling or homogenization if smaller particle size is needed for syringeability through fine needles. Published data for this specific configuration is limited.

Low-Moisture Grade Differentiation Against 50 µm, Standard 100 µm, and 180 µm MCC Products

Pharmacel 112 differs from the 50 µm grade primarily in particle size. The smaller grade has higher specific surface area and can produce higher compact hardness at equivalent compression force, but it exhibits poorer flow and greater dusting. Pharmacel 112 is therefore selected when direct compression or capsule filling requires adequate flow without the need for wet granulation. Compared with a standard 100 µm grade, the main difference is the tighter moisture limit of ≤ 3.0%. The standard grade is acceptable for many formulations, but the low-moisture variant is intended for actives that degrade by hydrolysis or interact with water. The coarse 180 µm grade provides better flow but lower compactibility; it may not be appropriate for low-dose blends because segregation risk increases with larger particle size. The following table summarizes the practical differences.

These comparisons are based on nominal supplier data; lot-to-lot variation requires verification against current technical datasheets. Compared with lactose monohydrate, Pharmacel 112 provides plastic deformation and partial disintegration, whereas lactose is brittle and water-soluble; this changes the disintegration mechanism. Compared with dibasic calcium phosphate dihydrate, microcrystalline cellulose has lower density and better compactibility but can retain moisture. Selection among these fillers is governed by active stability, flow, compaction profile, and disintegration requirements.

When Pharmacel 112 Is Substituted for Standard MCC in Moisture-Sensitive Dosage Forms

Substitution should not be treated as a simple drop-in. The reduced initial moisture of ≤ 3.0% lowers the water load entering the formulation, but it does not remove the need for environmental control. If the powder is held in open containers at relative humidity above 60%, moisture uptake can occur within hours and erode the advantage. Pre-drying in a fluid-bed dryer at 40–50 °C until loss on drying is below 3.0% is recommended before direct compression of moisture-sensitive actives. The formulation pH should remain within 5.0–7.0; strongly acidic or alkaline conditions can depolymerize cellulose and alter the degree of polymerization. Oxidation by strong oxidizing agents should also be avoided because it can reduce molecular weight and change compressibility. The substitution from standard MCC to Pharmacel 112 may require adjustment of lubricant concentration and compression force, because lower residual water reduces the plasticizing effect of moisture and can slightly reduce compactibility. Tablet hardness, friability per USP <1216> or Ph. Eur. 2.9.7, and disintegration time per USP <701> / Ph. Eur. 2.9.1 should be re-qualified after substitution.

In capsule products, moisture-sensitive actives in the same formulation may be protected by the low-moisture excipient, but desiccant requirements in the final pack should be determined by stability studies under ICH Q1A conditions. The low-moisture grade does not eliminate the need for barrier packaging; it reduces the water contribution from the excipient fraction only. Published data for this specific configuration is limited.